Aktie A3D12M BIOXYTRAN, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Bioxytran, Inc.

Aktien

A3D12M

US09075D1028

BIXT

Markt geschlossen - OTC Markets
Andere Börsenplätze
 20:54:51 07.05.2024 		% 5 Tage % 1. Jan.
0,1075 USD +5,39 % Intraday Chart für Bioxytran, Inc. -3,24 % -28,33 %
19.04. Bioxytran, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
19.04. Bioxytran, Inc. kündigt Änderungen im Vorstand an CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Bioxytran, Inc. Announces Board Changes
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
Bioxytran, Inc. Announces Preprint of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Bioxytran, Inc.'S Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for Covid-19
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Bioxytran Interview at the Emerging Growth Conference
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
Bioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patients
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
Bioxytran, Inc. Initiates A Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID 19 Patients
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
China metals export curbs lift shares in US producer MP Materials
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D12M Aktie
  4. Nachrichten Bioxytran, Inc.
  5. Andere Sprachen